(PGNY) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Progyny Inc. (NASDAQ: PGNY)'s price dynamics and execution-aware positioning, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents institutional trading strategies for various risk profiles, including long, momentum breakout, and short positions, along with multi-timeframe signal analysis and support/resistance levels. The analysis emphasizes the utility of AI models for risk management and position sizing.
Progyny (PGNY) Expected to Announce Earnings on Thursday
Progyny (NASDAQ:PGNY) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting earnings per share of $0.38. The company currently holds a "Moderate Buy" consensus rating from Wall Street with an average target price of $29.80, and institutional investors have a high ownership stake of approximately 94.93%. Recent institutional activity indicates strong interest, with firms like Wellington Management significantly increasing their positions.
CenterBook Partners LP Acquires 310,516 Shares of Progyny, Inc. $PGNY
CenterBook Partners LP significantly increased its stake in Progyny, Inc. by 272.7% in Q3, acquiring 310,516 additional shares to hold a total of 424,393 shares valued at approximately $9.13 million. Other institutional investors like Ameriprise, Jupiter Asset Management, Nomura Holdings Inc., Fort Washington Investment Advisors, and Principal Financial Group Inc. also raised their positions, contributing to Progyny's high institutional ownership of 94.93%. Analysts currently have a "Moderate Buy" rating on Progyny, with a consensus target price of $29.80 against its current trading price near $20.35.
Public Sector Pension Investment Board Buys 104,026 Shares of Progyny, Inc. $PGNY
The Public Sector Pension Investment Board increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 40.9% in the third quarter, acquiring an additional 104,026 shares, bringing its total holdings to 358,234 shares valued at approximately $7.71 million. Several other institutional investors also adjusted their positions in the company. Analysts maintain a "Moderate Buy" consensus rating for Progyny, with a target price of $29.80.
Progyny Inc (NASDAQ:PGNY) Passes the Caviar Cruise Quality Investing Screen
Progyny Inc (NASDAQ:PGNY) has successfully passed the "Caviar Cruise" quality investing screen, which identifies companies with strong competitive strengths, consistent profitability, a sound financial condition, and high returns on capital. The company excels in sales and EBIT growth, capital utilization with an exceptional ROIC of 30.82%, and maintains a debt-free balance sheet with high-grade earnings. This positions Progyny as a strong candidate for long-term, quality-centered investment portfolios, despite its premium valuation.
Progyny, Inc. to Announce Q4 and Full Year 2025 Financial Results on February 26, 2026
Progyny, Inc. will release its financial results for the fourth quarter and full year ending December 31, 2025, on February 26, 2026, after market close, followed by a conference call. The company, a global leader in women's health and family building solutions, has seen insider trading activity and institutional investor shifts, with recent analyst ratings and price targets also noted. An audio replay of the call will be available, and additional company information can be found on its website.
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report
Progyny, Inc. (Nasdaq: PGNY) will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. The company will host a conference call at 4:45 p.m. Eastern Time to discuss the results. Interested parties can access the call via phone or webcast, with a replay available until March 5, 2026.
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report
Progyny, Inc. (Nasdaq: PGNY) will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market closes on Thursday, February 26, 2026. The company will host a conference call at 4:45 p.m. ET to discuss the results. Both a live webcast and an archived replay will be available on Progyny's investor relations website.
Progyny, Inc. to Announce Q4 and Full Year 2025 Financial Results on February 26, 2026
Progyny, Inc. (PGNY) will release its Q4 and full-year 2025 financial results on February 26, 2026, after market close, followed by a conference call at 4:45 p.m. ET. The company, a leader in women's health and family building solutions, is recognized for optimizing clinical outcomes and reducing healthcare costs. Recent insider trading activity shows more sales than purchases, while institutional investors have mixed views, with some adding and others decreasing positions.
Progyny Adjusts Evaluation Amid Strong Growth and Financial Resilience
Progyny, Inc. has adjusted its evaluation due to changes in technical indicators, moving from mildly bullish to neutral, despite maintaining strong long-term fundamentals. The company shows impressive financial health with a 16.65% Return on Equity, significant growth in net sales and operating profit, and a low debt-to-equity ratio. Progyny has also outperformed the S&P 500 over the past year, highlighting its resilience and potential.
Progyny, Inc. $PGNY Shares Purchased by Principal Financial Group Inc.
Principal Financial Group Inc. significantly increased its stake in Progyny, Inc. by 57.1% during the third quarter, now holding 704,267 shares valued at $15.16 million. This comes as analysts maintain a "Moderate Buy" consensus rating for PGNY with an average price target of $29.36. Insider activity also shows CEO Peter Anevski purchasing 79,500 shares, boosting his ownership, while other institutional investors have adjusted their positions in the company.
(PGNY) as a Liquidity Pulse for Institutional Tactics
This article analyzes Progyny Inc. (NASDAQ: PGNY) with findings indicating weak near and mid-term sentiment but a positive long-term outlook. Key support levels are being tested, and a significant 47.2:1 risk-reward setup is identified, targeting a 13.1% gain with minimal risk. The analysis includes AI-generated institutional trading strategies for various risk profiles and time horizons.
Progyny, Inc. (NASDAQ:PGNY) Receives Average Rating of "Moderate Buy" from Brokerages
Progyny, Inc. (NASDAQ:PGNY) has received a "Moderate Buy" consensus rating from thirteen analysts, with an average one-year price target of $29.36. The company recently reported better-than-expected quarterly earnings of $0.45 EPS on $313.35 million in revenue, beating analyst estimates. While institutions own a significant portion of the company, insider activity shows a mix of buying by the CEO and selling by the CFO.
Progyny’s Financial Milestone: Upcoming Report to Set Direction
Progyny Inc. shares are trading within a narrow range, with investor focus on the upcoming release of its fourth-quarter and full-year 2025 financial report. Analysts are keen to see if the company meets its adjusted EPS targets and will closely examine management's commentary on client acquisition for 2026. Insider activity, including a significant investment by the CEO, adds to the narrative of anticipation for the February 26th report, which will be crucial for evaluating the company's future trajectory.
Progyny, Inc. $PGNY Shares Sold by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans significantly reduced its stake in Progyny, Inc. (NASDAQ:PGNY) by 55.9% in the third quarter of 2025, selling over 2.7 million shares. Despite this, Progyny reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and has a "Moderate Buy" consensus rating from analysts with an average target price of $29.36. Insider transactions were mixed, with CEO Peter Anevski increasing his holdings while CFO Mark Livingston sold shares.
(PGNY) Risk Channels and Responsive Allocation
Progyny Inc. (NASDAQ: PGNY) is currently facing weak near and mid-term sentiment, although its long-term outlook remains neutral. Despite support being tested, the stock presents an exceptional 42.4:1 risk-reward setup, targeting a 12.2% gain against a minimal 0.3% risk. The article details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis.
105,000 Shares in Progyny, Inc. $PGNY Acquired by Hussman Strategic Advisors Inc.
Hussman Strategic Advisors Inc. acquired 105,000 shares of Progyny (NASDAQ:PGNY) in Q3, valued at $2.26 million, contributing to institutional investors now owning 94.93% of the company. CEO Peter Anevski increased his stake by 13.23% by purchasing 79,500 shares, while CFO Mark Livingston sold 21,303 shares. Progyny reported strong Q3 earnings, beating estimates with $0.45 EPS and $313.35 million in revenue, and analysts maintain a "Moderate Buy" rating with an average target of $29.36.
Progyny, Inc. (PGNY) Investor Outlook: Analyzing a Promising 24.43% Potential Upside in Healthcare Plans
Progyny, Inc. (PGNY), a healthcare benefits management company focused on fertility and family-building benefits, is showing a positive investor outlook with a potential upside of 24.43%. The company, valued at $2.14 billion with a consensus target price of $30.91, demonstrates strong revenue growth, profitability, and robust free cash flow. Despite some short-term volatility and unavailable P/E and Price/Book ratios, analysts maintain a strong "buy" consensus, highlighting Progyny's innovative services and growth strategy.
Kornitzer Capital Management Inc. KS Sells 85,000 Shares of Progyny, Inc. $PGNY
Kornitzer Capital Management Inc. KS reduced its stake in Progyny, Inc. by 16.6% in the third quarter, selling 85,000 shares, though it still holds 426,931 shares. Insider activity was mixed, with CEO Peter Anevski buying shares and CFO Mark S. Livingston selling. Progyny exceeded Q3 earnings expectations and received a "Moderate Buy" rating from analysts with a consensus price target of $29.36.
Progyny Inc (NASDAQ:PGNY) Combines Strong Fundamentals with Bullish Technical Setup
Progyny Inc (NASDAQ:PGNY) is highlighted as an attractive investment opportunity due to its strong fundamental growth and bullish technical setup. The company shows significant revenue and earnings acceleration, solid financial health, and profitability, combined with a technical price formation indicating a potential upward move. This blended approach identifies stocks where fundamental momentum is likely to be recognized by the market, making PGNY a prime example.
Progyny Inc (PGNY) Stock Price Up 2.94% on Jan 20
Progyny Inc (PGNY) saw its stock price increase by 2.94% on January 20, reaching an intraday high of $25.67 before closing at $25.24. This places the stock 12.21% below its 52-week high and 40.41% above its 52-week low. Wall Street analysts have an average target price of $30.20, implying a 19.65% upside, with a consensus "Outperform" recommendation.
SG Americas Securities LLC Cuts Stock Position in Progyny, Inc. $PGNY
SG Americas Securities LLC significantly reduced its stake in Progyny, Inc. ($PGNY) by 75% in the third quarter, selling 98,646 shares. While institutional investors showed mixed activity, insider trades also varied with the CFO selling shares and the CEO purchasing a substantial number, increasing his ownership. Progyny reported strong Q3 earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating from analysts.
Progyny, Inc. (PGNY) supported by analysts as earnings visibility improves
This article from MSN suggests that analysts are showing support for Progyny, Inc. (PGNY). The improved earnings visibility for the company is cited as a key factor contributing to this positive sentiment.
Progyny, Inc. (PGNY) Supported by Analysts as Earnings Visibility Improves
Analysts are supportive of Progyny, Inc. (PGNY) due to improving earnings visibility. Truist upgraded PGNY to Buy and raised its price target, citing strong demand outside of Amazon and the company's cautious guidance strategy. KeyBanc also increased its price target, maintaining an Overweight rating, as it expects fundamental inflection in healthcare IT stocks after a volatile year.
Progyny (NASDAQ:PGNY) Upgraded by Citizens Jmp to "Market Outperform" Rating
Citizens Jmp has upgraded Progyny (NASDAQ:PGNY) from "market perform" to "market outperform," setting a $30 price target, suggesting a 22.35% upside. This upgrade aligns with a consensus "Moderate Buy" rating for the stock, which recently surpassed Q3 earnings and revenue estimates. Insider activity includes a significant purchase by the CEO and a sale by the CFO, while institutional investors hold approximately 94.9% of the shares.
Progyny Shows Rising Price Performance With Jump To 82 RS Rating
Progyny (PGNY) has seen its Relative Strength Rating increase from 77 to 82, surpassing the important 80 threshold for strong technical performance. This upgrade indicates improving price action over the last 52 weeks. The stock has been showing a trend of rising technical strength, as indicated by several recent RS rating improvements.
Progyny sees IBD RS rating climb to 77
Progyny (PGNY) has seen its IBD Relative Strength rating improve to 77. This indicates a positive shift in its stock performance compared to other companies in the market, suggesting a potential area of interest for investors.
Progyny Sees IBD RS Rating Climb To 77
Progyny (PGNY) saw its Relative Strength (RS) Rating improve from 67 to 77. This rating, measured by IBD, assesses a stock's price performance compared to others over the last 52 weeks, indicating market leadership. This recent increase reflects a positive trend in the company's technical strength.
Short Interest in Progyny, Inc. (NASDAQ:PGNY) Declines By 23.3%
Short interest in Progyny, Inc. (NASDAQ:PGNY) decreased by 23.3% in December, with 4,348,246 shares short as of December 31st. This represents 5.6% of the company's shares and a days-to-cover ratio of 3.1. The decline in short interest follows insider buying by CEO Peter Anevski and strong earnings results, which beat analyst estimates and led to upward revisions in price targets from several research firms.
Progyny, Inc. (NASDAQ:PGNY) Receives Average Recommendation of "Moderate Buy" from Brokerages
Progyny, Inc. (NASDAQ:PGNY) has received an average "Moderate Buy" rating from brokerages, with several analysts recently upgrading their recommendations and an average 1-year price target of $28.40. While CFO Mark Livingston sold shares, CEO Peter Anevski made a substantial purchase, and insiders collectively own about 9.4% of the stock. The company recently exceeded Q3 earnings and revenue estimates but saw its shares decline post-announcement, with a market capitalization of roughly $2.18 billion.
(PGNY) Movement as an Input in Quant Signal Sets
This article analyzes Progyny Inc. (NASDAQ: PGNY) using AI models to generate trading signals and strategies. It highlights a weak near-term sentiment but an exceptional risk-reward setup, targeting a 12.7% gain against 0.3% risk. The analysis includes institutional trading strategies for different risk profiles and multi-timeframe signal analysis, providing support and resistance levels.
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
Progyny, Inc. announced its participation in the 44th Annual JP Morgan Healthcare Conference, where it will discuss updated financial expectations for the fourth quarter and full year ending December 31, 2025. The company expects fourth-quarter revenue, net income, and Adjusted EBITDA to be slightly above previously issued guidance due to favorable member engagement. CEO Pete Anevski, CFO Mark Livingston, COO Melissa Cummings, and CCO Katie Higgins will represent Progyny at the conference.
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY)
Healthcare analysts have issued bullish ratings for Boston Scientific (BSX), Regeneron (REGN), and Progyny (PGNY). Truist Financial maintained Buy ratings on all three companies, citing strong upside potential for Boston Scientific and Regeneron, while Progyny also received a Buy rating with a modest upside. Bank of America Securities also reiterated Buy ratings for these firms.
Progyny Stock (-11%) : JPM Conference Growth Narrative Fails to Impress
The article reports that Progyny's stock dropped by 11% following the JPM Conference. The growth narrative presented by the company at the conference apparently failed to impress investors, leading to a significant decline in its stock price.
Progyny, Inc.'s (NASDAQ:PGNY) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Progyny's stock has surged by 40% in three months, but its fundamentals suggest an inconsistent financial health. The company's 10% ROE is lower than the industry average of 15%, which may explain its low net income growth of 2.8% over the past five years. Despite this, analysts forecast an acceleration in the company's earnings.
Family-building firm Progyny now expects stronger year-end results
Progyny (Nasdaq: PGNY) anticipates its fourth quarter and full-year 2025 financial results to be slightly above previous guidance due to better-than-expected member engagement. The company will discuss these updated expectations at the JP Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. ET. This news led to a 5.30% increase in PGNY's stock price on the day of the announcement.
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
Progyny, Inc. announced it will discuss updated financial expectations at the 44th Annual JP Morgan Healthcare Conference, anticipating fourth-quarter and full-year 2025 results to be slightly above previous guidance. The company's CEO, Pete Anevski, highlighted favorable member engagement. A live audiocast of their presentation will be available on their investor relations website.
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
Progyny, Inc. announced its participation in the 44th Annual JP Morgan Healthcare Conference, where it will discuss updated financial expectations for the quarter and year ending December 31, 2025. The company anticipates results to be slightly above previously provided guidance due to favorable member engagement. CEO Pete Anevski, along with other key executives, will present at the conference.
Progyny stock to exceed guidance as BofA reiterates Buy rating By Investing.com
Progyny (NASDAQ:PGNY) announced it expects to surpass its previously issued guidance for the fourth quarter and full-year 2025, driven by favorable member engagement. BofA Securities reiterated a Buy rating on the stock with a $30.00 price target, noting the company's strong financial health and consistent growth. This positive outlook follows recent upgrades from other firms and a successful selling season for the fertility benefits management company.
Progyny stock to exceed guidance as BofA reiterates Buy rating
Progyny (NASDAQ:PGNY) announced expectations to exceed its Q4 and full-year 2025 guidance, driven by favorable member engagement. BofA Securities reiterated a Buy rating with a $30 price target, aligning with other analysts who have recently upgraded the stock and raised price targets. Despite trading near its 52-week high, InvestingPro Fair Value analysis suggests the stock remains undervalued.
Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
Progyny, Inc. announced it will discuss updated financial expectations at the 44th Annual JP Morgan Healthcare Conference on January 13, 2026. The company anticipates its fourth-quarter and full-year 2025 revenue, net income, and Adjusted EBITDA to be slightly above previous guidance. This positive outlook is attributed to favorable member engagement in the fourth quarter.
Progyny, Inc.'s (NASDAQ:PGNY) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Progyny's stock has seen a significant 32% rally in the past three months, but its financials, particularly its Return on Equity (ROE), present a mixed picture. With a 10% ROE falling below the industry average of 15% and low net income growth of 2.8% over five years, the company's efficiency in reinvesting profits is questioned despite not paying dividends. While analyst forecasts indicate an expected acceleration in earnings, investors are advised to consider these fundamental ambiguities.
Progyny, Inc. (PGNY) Soars to 52-Week High, Time to Cash Out?
Progyny (PGNY) recently hit a new 52-week high after a strong performance, outperforming its sector and industry. The company has a history of beating earnings estimates and holds a Zacks Rank #2 (Buy), suggesting potential for continued growth. While valuation metrics show mixed signals, its strong earnings estimate revision trend makes it an attractive option for investors.
Truist Securities upgrades Progyny stock rating to Buy on improved outlook By Investing.com
Truist Securities has upgraded Progyny (NASDAQ:PGNY) from Hold to Buy, increasing its price target to $34.00, citing an improved outlook and stable demand trends for the fertility benefits management company. This upgrade is supported by Progyny's 11.41% revenue growth over the past year and analysts revising earnings estimates upward, reflecting confidence in the company's strategic adjustments to past utilization-driven volatility. Other firms like Cantor Fitzgerald and KeyBanc have also recently upgraded Progyny and raised their price targets, signaling significant interest in the company's offerings.
Progyny stock hits 52-week high at 27.84 USD By Investing.com
Progyny Inc. (NASDAQ:PGNY) stock reached a new 52-week high of $27.84, reflecting a 46.85% increase over the past year and underscoring strong market performance with a $2.31 billion market capitalization. The company’s revenue hit $1.27 billion in the last twelve months, and analysts expect net income growth. Additionally, recent news includes strong Q3 2025 earnings, an increased full-year revenue outlook, a $200 million share repurchase program, and an analyst upgrade to Overweight due to growing demand for fertility benefits.
Truist Securities upgrades Progyny stock rating to Buy on improved outlook
Truist Securities upgraded Progyny (NASDAQ:PGNY) from Hold to Buy and raised its price target to $34.00, citing stable demand trends, improved outlook, and a more conservative guidance approach. The firm believes previous market worries regarding ProgynyRx were misplaced and that strategic adjustments have created a more favorable investment setup despite potential volatility. This upgrade follows recent positive reports including increased Q3 2025 revenue, raised full-year guidance, and other analyst upgrades.
Progyny (NASDAQ:PGNY) stock performs better than its underlying earnings growth over last year
Progyny (NASDAQ:PGNY) stock has seen a 47% increase over the last year, outperforming the general market, despite its EPS only growing by 5.2% during the same period. This indicates increased market optimism for the stock. While longer-term shareholders have faced tougher times, recent insider buying suggests a positive outlook, although investors are advised to examine historical growth trends.
Truist Securities upgrades Progyny stock rating to Buy on improved outlook
Truist Securities upgraded Progyny (NASDAQ:PGNY) from Hold to Buy, raising its price target to $34.00, aligning with InvestingPro’s Fair Value assessment. The upgrade reflects an improved outlook for the fertility benefits management company, stable demand trends, and strategic adjustments to guidance. This follows recent positive news including increased revenue, a raised full-year guidance, and a share repurchase program.
Progyny (PGNY) Stock Hits New High: Keybanc Raises Target to $32 - News and Statistics
Shares of Progyny (PGNY) surged 4.9% to a new 52-week high after Keybanc analyst Scott Schoenhaus maintained an Overweight rating and raised the price target to $32.00 from $30.00. This upgrade reflects continued confidence in the company's financial performance, driven by strong demand for its fertility benefits. Despite the initial morning surge, the stock later stabilized, ending the day with a 3% increase.
Progyny (PGNY) Stock Is Up, What You Need To Know
Progyny (NASDAQ:PGNY) shares jumped 4.9% after Keybanc analyst Scott Schoenhaus maintained an 'Overweight' rating and raised the price target to $32.00 from $30.00. The positive outlook is driven by strong demand for fertility benefits, leading to significant year-over-year revenue and profit gains, and the stock reached a new 52-week high before settling at $27.60. The market views this news as meaningful, adding to the stock's 7.2% gain since the start of the year.
